JP2022509826A - デフルビーモナス属(Defluviimonas)種由来のCas9タンパク質に基づくDNAカット手段 - Google Patents
デフルビーモナス属(Defluviimonas)種由来のCas9タンパク質に基づくDNAカット手段 Download PDFInfo
- Publication number
- JP2022509826A JP2022509826A JP2021529804A JP2021529804A JP2022509826A JP 2022509826 A JP2022509826 A JP 2022509826A JP 2021529804 A JP2021529804 A JP 2021529804A JP 2021529804 A JP2021529804 A JP 2021529804A JP 2022509826 A JP2022509826 A JP 2022509826A
- Authority
- JP
- Japan
- Prior art keywords
- dna
- sequence
- protein
- amino acid
- dfcas9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004414 DNA Proteins 0.000 title claims abstract description 122
- 108091033409 CRISPR Proteins 0.000 title abstract description 40
- 241001569001 Defluviimonas Species 0.000 title abstract 2
- 238000005520 cutting process Methods 0.000 title description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 26
- 230000005782 double-strand break Effects 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 108020005004 Guide RNA Proteins 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- 102000053602 DNA Human genes 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 150000002500 ions Chemical class 0.000 claims description 10
- 108091029865 Exogenous DNA Proteins 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 abstract description 31
- 239000013612 plasmid Substances 0.000 abstract description 15
- 238000012986 modification Methods 0.000 abstract description 13
- 230000004048 modification Effects 0.000 abstract description 13
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 abstract description 9
- 230000001580 bacterial effect Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 34
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 238000010354 CRISPR gene editing Methods 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 7
- 108091027544 Subgenomic mRNA Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 101100026538 Homo sapiens GRIN2B gene Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 108091079001 CRISPR RNA Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910001437 manganese ion Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108010015268 Integration Host Factors Proteins 0.000 description 2
- 230000009948 RNA mutation Effects 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000007064 DNA hydrolysis Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101100326871 Escherichia coli (strain K12) ygbF gene Proteins 0.000 description 1
- 101100438439 Escherichia coli (strain K12) ygbT gene Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 101100329497 Thermoproteus tenax (strain ATCC 35583 / DSM 2078 / JCM 9277 / NBRC 100435 / Kra 1) cas2 gene Proteins 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 101150000705 cas1 gene Proteins 0.000 description 1
- 101150117416 cas2 gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
1xTris-HCl緩衝液、pH=7.9(25℃)400nM
DfCas9
20nM DNAターゲット
2μM crRNA
2μM tracrRNA
1mMの対応するイオンの塩
総反応体積は20μlであり、反応時間は30分間であり、そしてインキュベーション温度は37℃であった。
実施例1. 多様なDNAターゲットのカットにおけるDfCas9タンパク質の活性の試験。
DfCas9ヌクレアーゼ活性に対するMn2+イオンの影響を試験するため、コンセンサス配列3’-NN(G/A)NA(C/T)-5’を有するPAM配列
反応は、tracrRNA:
図7は、5mMから10mMへのMnCl2の濃度の増加が、DNAターゲットのより効率的なカットを生じる一方、二価イオン濃度のさらなる増加は、反応効率に影響を及ぼさないことを示した。したがって、有効なDfCas9活性は、10mMまたはそれより高い濃度でのマンガンイオンの存在を必要とする。
sgRNAは、ガイドRNAの1つの型であり、融合したtracrRNA(トレーサーRNA)およびcrRNAである。最適なsgRNAを選択するため、本発明者らは、tracrRNA-crRNA二重鎖の長さが異なる、この配列の3つの変異体を構築した。RNAをin vitroで合成し、そしてDNAターゲットのカットにおいて、これらに対する実験を行った(図8は、多様なsgRNA変異体を用いたDfCas9によるDNAのカット反応を示す)。
DNAターゲットと直接対形成する配列を修飾する際、sgRNAのこの変異体を用いて、任意の他のターゲットDNAをカットしてもよい。
実施例4. デフルビーモナス属種に属する近縁生物由来のCas9タンパク質。
遺伝子操作の当業者は、本出願者らによって得られ、そして特徴づけられているDfCas9タンパク質配列変異体を、タンパク質自体の機能を変化させずに修飾しうる(例えば機能活性に直接影響を及ぼさないアミノ酸残基の部位特異的突然変異誘発によって(Sambrookら, Molecular Cloning: A Laboratory Manual, (1989), CSH Press, pp.15.3-15.108))ことを認識するであろう。特に、当業者は、タンパク質機能性に関与する(タンパク質機能または構造を決定する)残基に影響を及ぼすことなく、非保存性アミノ酸残基を修飾しうることを認識するであろう。こうした修飾の例には、相同のものでの非保存性アミノ酸残基の置換が含まれる。非保存性アミノ酸残基を含有する領域のいくつかを図9に示す。本発明のいくつかの態様において、配列番号1のアミノ酸配列に少なくとも95%同一であり、そして非保存性アミノ酸残基でのみ配列番号1と異なるアミノ酸配列を含むタンパク質を使用して、DNA分子において、前記DNA分子中のヌクレオチド配列5’-NN(G/A)NA(C/T)N-3’の直前に位置する二本鎖切断を形成することが可能である。対応する核酸分子を突然変異誘発(例えば部位特異的またはPCR仲介性突然変異誘発)することによって、相同タンパク質を得て、その後、本明細書に記載する機能分析にしたがって、その機能の保持に関して、コードされる修飾Cas9タンパク質を試験してもよい。
トレーサーRNA発現カセットは、以下のようになる:
プラスミドDNAを精製し、そしてLipofectamine 2000試薬(Thermo Fisher Scientific)を用いて、ヒトHEK293細胞内にトランスフェクションする。細胞を72時間インキュベーションし、その後、ゲノムDNA精製カラム(Thermo Fisher Scientific)を用いて、そこからゲノムDNAを抽出する。定向性二本鎖切断、その後、その修復によりターゲット部位で行われたDNA中の挿入/欠失の数を決定するため、Illuminaプラットフォーム上で配列決定することによって、ターゲットDNA部位を分析する。
深海細菌デフルビーモナス属種20V17由来の本発明で特徴づけられるDfCas9ヌクレアーゼは、以前特徴づけられたCas9タンパク質に比較して、いくつかの利点を有する。例えば、DfCas9は、他の既知のCasヌクレアーゼとは異なり、比較的単純な3文字PAMを有し、PAMは系が機能するのに必要である。DNA中に二本鎖切断を導入可能な現在知られるCasヌクレアーゼの大部分は、多文字の複雑なPAMを有し、これがカットに適切な配列の選択を制限する。今日までに研究される、短いPAMを認識するCasヌクレアーゼの中で、DfCas9のみが、5’-NN(G/A)NA(C/T)N-3’ヌクレオチドに制限された配列を認識しうる。
Claims (5)
- DNA分子中のヌクレオチド配列5’-NN(G/A)NA(C/T)N-3’の直前に位置する、前記DNA分子中の二本鎖切断を形成するための、配列番号1のアミノ酸配列を含むか、または配列番号1のアミノ酸配列に少なくとも95%同一であり、そして非保存性アミノ酸残基でのみ配列番号1と異なるアミノ酸配列を含む、タンパク質の使用。
- 35℃~37℃の温度で、そしてMn2+イオンの存在下で、DNA分子中に二本鎖切断が形成されることで特徴づけられる、請求項1記載の使用。
- タンパク質が配列番号1のアミノ酸配列を含む、請求項1記載のタンパク質の使用。
- 配列5’-NN(G/A)NA(C/T)N-3’に直接隣接する、単細胞または多細胞生物のゲノムDNA配列中に二本鎖切断を生成するための方法であって、該生物の少なくとも1つの細胞内に、有効量の:a)配列番号1のアミノ酸配列を含むタンパク質、または配列番号1のアミノ酸配列を含むタンパク質をコードする核酸、並びにb)ヌクレオチド配列5’-NN(G/A)NA(C/T)N-3’にすぐ隣接する生物のゲノムDNA領域のヌクレオチド配列と二重鎖を形成し、そして二重鎖形成後に前記タンパク質と相互作用する配列を含むガイドRNA、または前記ガイドRNAをコードするDNA配列、を導入する工程を含む、
ここで、前記タンパク質と該ガイドRNAおよびヌクレオチド配列5’-NN(G/A)NA(C/T)N-3’の間の相互作用が、配列5’-NN(G/A)NA(C/T)N-3’に直接隣接するゲノムDNA配列中の二本鎖切断の形成を生じる
前記方法。 - ガイドRNAと同時に、外因性DNA配列の導入をさらに含む、請求項4記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018141534A RU2712492C1 (ru) | 2018-11-26 | 2018-11-26 | Средство разрезания днк на основе cas9 белка из defluviimonas sp. |
RU2018141534 | 2018-11-26 | ||
PCT/RU2019/050230 WO2020111984A2 (ru) | 2018-11-26 | 2019-11-26 | Средство разрезания днк на основе cas9 белка из defluviimonas sр. |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022509826A true JP2022509826A (ja) | 2022-01-24 |
Family
ID=69625403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021529804A Pending JP2022509826A (ja) | 2018-11-26 | 2019-11-26 | デフルビーモナス属(Defluviimonas)種由来のCas9タンパク質に基づくDNAカット手段 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220017896A1 (ja) |
EP (1) | EP3889270A4 (ja) |
JP (1) | JP2022509826A (ja) |
KR (1) | KR20210118817A (ja) |
CN (1) | CN113614247A (ja) |
AU (1) | AU2019388217A1 (ja) |
BR (1) | BR112021010186A2 (ja) |
CA (1) | CA3121089A1 (ja) |
CL (1) | CL2021001381A1 (ja) |
CO (1) | CO2021006937A2 (ja) |
EA (1) | EA202191505A1 (ja) |
MA (1) | MA53578B1 (ja) |
MX (1) | MX2021006118A (ja) |
PE (1) | PE20212083A1 (ja) |
PH (1) | PH12021551202A1 (ja) |
RU (1) | RU2712492C1 (ja) |
WO (1) | WO2020111984A2 (ja) |
ZA (1) | ZA202103582B (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3226329A1 (en) * | 2011-12-16 | 2013-06-20 | Targetgene Biotechnologies Ltd | Compositions and methods for modifying a predetermined target nucleic acid sequence |
US8697359B1 (en) * | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
RU2716420C2 (ru) * | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
AU2016263026A1 (en) * | 2015-05-15 | 2017-11-09 | Pioneer Hi-Bred International, Inc. | Guide RNA/Cas endonuclease systems |
WO2018035388A1 (en) * | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
CN112020554A (zh) * | 2018-02-23 | 2020-12-01 | 先锋国际良种公司 | 新颖cas9直系同源物 |
-
2018
- 2018-11-26 RU RU2018141534A patent/RU2712492C1/ru active
-
2019
- 2019-11-26 CN CN201980090347.0A patent/CN113614247A/zh active Pending
- 2019-11-26 JP JP2021529804A patent/JP2022509826A/ja active Pending
- 2019-11-26 WO PCT/RU2019/050230 patent/WO2020111984A2/ru unknown
- 2019-11-26 EA EA202191505A patent/EA202191505A1/ru unknown
- 2019-11-26 KR KR1020217019951A patent/KR20210118817A/ko unknown
- 2019-11-26 US US17/296,629 patent/US20220017896A1/en active Pending
- 2019-11-26 BR BR112021010186-1A patent/BR112021010186A2/pt unknown
- 2019-11-26 MA MA53578A patent/MA53578B1/fr unknown
- 2019-11-26 EP EP19891145.5A patent/EP3889270A4/en active Pending
- 2019-11-26 MX MX2021006118A patent/MX2021006118A/es unknown
- 2019-11-26 AU AU2019388217A patent/AU2019388217A1/en active Pending
- 2019-11-26 PE PE2021000761A patent/PE20212083A1/es unknown
- 2019-11-26 CA CA3121089A patent/CA3121089A1/en active Pending
-
2021
- 2021-05-25 PH PH12021551202A patent/PH12021551202A1/en unknown
- 2021-05-26 ZA ZA2021/03582A patent/ZA202103582B/en unknown
- 2021-05-26 CL CL2021001381A patent/CL2021001381A1/es unknown
- 2021-05-26 CO CONC2021/0006937A patent/CO2021006937A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PH12021551202A1 (en) | 2021-10-25 |
CO2021006937A2 (es) | 2021-09-20 |
CA3121089A1 (en) | 2020-06-04 |
EP3889270A4 (en) | 2022-08-24 |
EA202191505A1 (ru) | 2021-09-14 |
WO2020111984A2 (ru) | 2020-06-04 |
US20220017896A1 (en) | 2022-01-20 |
MX2021006118A (es) | 2021-07-07 |
MA53578B1 (fr) | 2022-10-31 |
CN113614247A (zh) | 2021-11-05 |
PE20212083A1 (es) | 2021-11-04 |
KR20210118817A (ko) | 2021-10-01 |
AU2019388217A1 (en) | 2021-07-08 |
EP3889270A2 (en) | 2021-10-06 |
CL2021001381A1 (es) | 2022-01-07 |
BR112021010186A2 (pt) | 2021-09-28 |
MA53578A1 (fr) | 2022-02-28 |
WO2020111984A3 (ru) | 2020-07-23 |
RU2712492C1 (ru) | 2020-01-29 |
ZA202103582B (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113234702B (zh) | 一种Lt1Cas13d蛋白及基因编辑系统 | |
EP4159853A1 (en) | Genome editing system and method | |
WO2023138082A1 (zh) | 一种真核生物来源的Argonaute蛋白及其应用 | |
Dong et al. | A single digestion, single-stranded oligonucleotide mediated PCR-independent site-directed mutagenesis method | |
JP2022509826A (ja) | デフルビーモナス属(Defluviimonas)種由来のCas9タンパク質に基づくDNAカット手段 | |
RU2788197C1 (ru) | Средство разрезания ДНК на основе Cas9 белка из бактерии Streptococcus uberis NCTC3858 | |
RU2778156C1 (ru) | Средство разрезания ДНК на основе Cas9 белка из бактерии Capnocytophaga ochracea | |
RU2791447C1 (ru) | Средство разрезания ДНК на основе ScCas12a белка из бактерии Sedimentisphaera cyanobacteriorum | |
RU2712497C1 (ru) | Средство разрезания ДНК на основе Cas9 белка из биотехнологически значимой бактерии Clostridium cellulolyticum | |
OA20197A (en) | DNA-cutting agent. | |
US20220228134A1 (en) | Dna-cutting agent based on cas9 protein from the bacterium pasteurella pneumotropica | |
EP4056705A1 (en) | Use of cas9 protein from the bacterium pasteurella pneumotropica | |
RU2722933C1 (ru) | Средство разрезания днк на основе cas9 белка из бактерии demequina sediminicola | |
EA041933B1 (ru) | Средство разрезания днк | |
EA042517B1 (ru) | Средство разрезания днк | |
EA041935B1 (ru) | СРЕДСТВО РАЗРЕЗАНИЯ ДНК НА ОСНОВЕ Cas9 БЕЛКА ИЗ БАКТЕРИИ Pasteurella Pneumotropica | |
OA20443A (en) | DNA-cutting agent based on CAS9 protein from the bacterium pasteurella pneumotropica | |
OA20196A (en) | DNA-cutting agent. | |
OA20812A (en) | Use of CAS9 protein from the bacterium pasteurella pneumotropica. | |
KR20240107373A (ko) | C2c9 뉴클레아제 기반의 신규 게놈 편집 시스템 및 이의 응용 | |
EA044419B1 (ru) | Применение cas9 белка из бактерии pasteurella pneumotropica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221027 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240123 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240612 |